$STTK
Shattuck Labs Inc Stock $sttk

$sttk Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000168036723000035 Filed on May 09, 2023

Income Statement

Concept	2023 Q2	2023 Q1
Revenue	$200.0K	$57.00K
YoY Change	300.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.742M	$5.051M
YoY Change	-0.06%	1.45%
% of Gross Profit
Research & Development	$18.21M	$16.67M
YoY Change	-20.72%	-13.13%
% of Gross Profit
Depreciation & Amortization	$1.027M	$1.014M
YoY Change	55.14%	114.83%
% of Gross Profit
Operating Expenses	$22.95M	$21.72M
YoY Change	-17.18%	-10.13%
Operating Profit	-$22.75M	-$21.66M
YoY Change	-17.76%	-10.37%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$1.401M	$937.0K
YoY Change	388.15%	-358.84%
Pretax Income	-$21.35M	-$20.72M
YoY Change	-22.01%	-15.51%
Income Tax
% Of Pretax Income
Net Earnings	-$21.35M	-$20.72M
YoY Change	-22.01%	-15.51%
Net Earnings / Revenue	-10673.0%	-36357.89%
Basic Earnings Per Share	-$0.50	-$0.49
Diluted Earnings Per Share	-$0.50	-$0.49
COMMON SHARES
Basic Shares Outstanding	42.47M shares	42.45M shares
Diluted Shares Outstanding	42.47M shares	42.44M shares

Balance Sheet

Concept	2023 Q2	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$117.2M	$135.5M
YoY Change	-45.31%	-43.36%
Cash & Equivalents	$71.89M	$66.04M
Short-Term Investments	$45.28M	$69.45M
Other Short-Term Assets	$19.28M	$22.34M
YoY Change	27.02%	41.74%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$136.5M	$157.8M
YoY Change	-40.52%	-38.1%
LONG-TERM ASSETS
Property, Plant & Equipment	$16.02M	$16.89M
YoY Change	-14.63%	37.58%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.805M	$2.953M
YoY Change	-11.35%	-8.52%
Total Long-Term Assets	$18.82M	$19.84M
YoY Change	-14.15%	27.98%
TOTAL ASSETS
Total Short-Term Assets	$136.5M	$157.8M
Total Long-Term Assets	$18.82M	$19.84M
Total Assets	$155.3M	$177.7M
YoY Change	-38.22%	-34.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.011M	$5.128M
YoY Change	-64.56%	97.76%
Accrued Expenses	$10.98M	$10.88M
YoY Change	-40.86%	-23.49%
Deferred Revenue	$743.0K
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$12.99M	$16.01M
YoY Change	-46.41%	-4.79%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$3.818M	$4.014M
YoY Change	-16.38%	-15.28%
Total Long-Term Liabilities	$3.818M	$4.014M
YoY Change	-16.38%	-15.28%
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.99M	$16.01M
Total Long-Term Liabilities	$3.818M	$4.014M
Total Liabilities	$16.81M	$20.02M
YoY Change	-41.65%	-7.09%
SHAREHOLDERS EQUITY
Retained Earnings	-$261.1M	-$239.7M
YoY Change	54.5%	69.28%
Common Stock	$5.000K	$5.000K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$138.5M	$157.7M
YoY Change
Total Liabilities & Shareholders Equity	$155.3M	$177.7M
YoY Change	-38.22%	-34.31%

Cashflow Statement

Concept	2023 Q2	2023 Q1
OPERATING ACTIVITIES
Net Income	-$21.35M	-$20.72M
YoY Change	-22.01%	-15.51%
Depreciation, Depletion And Amortization	$1.027M	$1.014M
YoY Change	55.14%	114.83%
Cash From Operating Activities	-$18.62M	-$26.46M
YoY Change	14.1%	0.7%
INVESTING ACTIVITIES
Capital Expenditures	$296.0K	$75.00K
YoY Change	-103.85%	-96.99%
Acquisitions
YoY Change
Other Investing Activities	$24.73M	$45.20M
YoY Change	122.46%	-450.55%
Cash From Investing Activities	$24.43M	$45.13M
YoY Change	611.71%	-393.36%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	33.00K	$0.00
YoY Change	230.0%	-100.0%
NET CHANGE
Cash From Operating Activities	-18.62M	-$26.46M
Cash From Investing Activities	24.43M	$45.13M
Cash From Financing Activities	33.00K	$0.00
Net Change In Cash	5.850M	$18.66M
YoY Change	-145.44%	-144.95%
FREE CASH FLOW
Cash From Operating Activities	-$18.62M	-$26.46M
Capital Expenditures	$296.0K	$75.00K
Free Cash Flow	-$18.91M	-$26.54M
YoY Change	119.07%	-7.75%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001680367
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2022#LicenseMember
CY2023Q1	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2022#LicenseMember
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-39593
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	Shattuck Labs, Inc.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	81-2575858
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	500 W. 5th Street
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1200
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Austin
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	78701
CY2023Q1	dei	City Area Code CityAreaCode	512
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	900-4690
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2023Q1	dei	Trading Symbol TradingSymbol	STTK
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	42471288	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	66043000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	47379000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	69452000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	113901000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	22342000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	23304000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	157837000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	184584000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	16887000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	17671000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2953000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3069000	usd
CY2023Q1	us-gaap	Assets Assets	177677000	usd
CY2022Q4	us-gaap	Assets Assets	205324000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	5128000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7170000	usd
CY2023Q1	sttk	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	10881000	usd
CY2022Q4	sttk	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	17795000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	16009000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	24965000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4014000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4202000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	20023000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	29167000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	42460258	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	42460258	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	42390586	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	42390586	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	5000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	5000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	397724000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	396041000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-339000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-877000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-239736000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-219012000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	157654000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	176157000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	177677000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	205324000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	57000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16667000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19187000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5051000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4979000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	21718000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	24166000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-21661000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-24166000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	937000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-362000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-20724000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-24528000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	538000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	33000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20186000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-24495000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.49
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.49
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.58
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.58
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42439204	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	42439204	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42357625	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	42357625	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	176157000	usd
CY2023Q1	sttk	Stock Issued During Period Value Stock Options Exercised And Espp Purchased StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased	39000	usd
CY2023Q1	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	16153	shares
CY2023Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	39000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1683000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	538000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-20724000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	157654000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	271786000	usd
CY2022Q1	sttk	Stock Issued During Period Value Stock Options Exercised And Espp Purchased StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased	134000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1513000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	33000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-24528000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	248938000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-20724000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-24528000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1683000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1513000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	1014000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	472000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	85000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	65000	usd
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	213000	usd
CY2022Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-981000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1462000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3699000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-30000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-25000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2197000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-7738000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-7356000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-601000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-188000	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-165000	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-57000	usd
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-26461000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-26277000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	75000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2488000	usd
CY2023Q1	us-gaap	Payments For Proceeds From Availableforsale Securities Shortterm PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm	-45200000	usd
CY2022Q1	us-gaap	Payments For Proceeds From Availableforsale Securities Shortterm PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm	12894000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	45125000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-15382000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	39000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	134000	usd
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	39000	usd
CY2022Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	134000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	18664000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-41525000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	47379000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	92268000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	66043000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	50743000	usd
CY2023Q1	sttk	Operating Lease Liabilities Recognized For Operating Lease Right Of Use Assets OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets	0	usd
CY2022Q1	sttk	Operating Lease Liabilities Recognized For Operating Lease Right Of Use Assets OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets	5447000	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2945000	usd
CY2023Q1	sttk	Revenue From Contract With Customer Deferred Revenue Billed Not Received RevenueFromContractWithCustomerDeferredRevenueBilledNotReceived	500000	usd
CY2022Q1	sttk	Revenue From Contract With Customer Deferred Revenue Billed Not Received RevenueFromContractWithCustomerDeferredRevenueBilledNotReceived	0	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	155000	usd
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	319000	usd
CY2023Q1	us-gaap	Nature Of Operations NatureOfOperations	Organization and Description of Business <div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shattuck Labs, Inc. (the “Company”) was incorporated in 2016 in the State of Delaware and is a clinical-stage biopharmaceutical company developing dual-sided fusion proteins, including its Agonist Redirected Checkpoint (“ARC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) and gamma delta T cell engager (“GADLEN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) platforms, as novel classes of biologic medicines capable of multifunctional activity with potential applications in oncology and inflammatory diseases. Using its proprietary technology, the Company is building a pipeline of therapeutics, initially focused on the treatment of solid tumors and hematologic malignancies. The Company has one clinical-stage product candidate, SL-172154, and has several compounds in preclinical development. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred losses and negative cash flows from operations since inception and has an accumulated deficit of $239.7 million as of March 31, 2023. The Company anticipates incurring additional losses and negative cash flows from operations until such time, if ever, that it can generate significant sales of its product candidates currently in development, and is highly dependent on its ability to find additional sources of funding in the form of licensing of its technology, collaboration agreements and/or public and private debt and equity financings. Adequate additional funding may not be available to the Company on acceptable terms, or at all. The failure to raise funds as and when needed could have a negative impact on the Company’s financial condition and ability to pursue its clinical operations, research and development and commercialization of its product candidates. Management believes that the Company’s cash and cash equivalents and investments of $135.5 million as of March 31, 2023 are sufficient to fund projected operations of the Company for at least the next twelve months. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Global Economic Considerations</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the global macroeconomic environment is uncertain, and could be negatively affected by, among other things, increased U.S. trade tariffs and trade disputes with other countries, instability in the global capital and credit markets, supply chain weaknesses, instability in the geopolitical environment, including as a result of the Russian invasion of Ukraine and other political tensions, and lingering effects of the COVID-19 pandemic. Such challenges have caused, and may continue to cause, recession fears, rising interest rates, foreign exchange volatility and inflationary pressures. At this time, we are unable to quantify the potential effects of this economic instability on our future operations.</span></div>
CY2023Q1	sttk	Number Of Clinical Stage Product Candidates NumberOfClinicalStageProductCandidates	1	candidate
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-239700000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	135500000	usd
CY2023Q1	sttk	Accrued Research And Contract Costs Current AccruedResearchAndContractCostsCurrent	6650000	usd
CY2022Q4	sttk	Accrued Research And Contract Costs Current AccruedResearchAndContractCostsCurrent	11256000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, revenue recognition, </span></div>the accrual of research and development expenses, and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates, if any, are recorded in the period in which they become known and actual results could differ from management’s estimates.
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risk </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and investments. The Company maintains its cash and cash equivalents at two accredited financial institutions in amounts that exceed federally-insured limits. While the Company has not experienced any losses, the recent failure of Silicon Valley Bank (“SVB”), at which the Company held cash, exposed the Company to significant credit risk prior to the completion by the Federal Deposit Insurance Corporation of the resolution of SVB in a manner that fully protected all depositors. The Company is in the process of transferring its cash to an alternate depository institution, the financial position of which management believes does not expose the Company to significant credit risk. Where possible, the Company will also continue to hold its excess cash in investments and money market accounts to further limit exposure. The Company does not believe that it is subject to other unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company invests in only U.S. Treasury securities that management believes protects the Company from risk of default and impairment of value.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is highly dependent on a limited number of contract manufacturing organizations (“CMOs”) to supply drug products for its research and development activities of its programs, including clinical trials and non-clinical studies. These programs could be adversely affected by a significant interruption in the supply of such drug products. </span></div>The Company is highly dependent on a limited number of contract research organizations (“CROs”) and third-party service providers to manage and support its clinical trials. These programs could be adversely affected by a significant disruption in services provided by these CROs and third parties.
CY2023Q1	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	usd
CY2022Q1	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	usd
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5914037	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3774301	shares
CY2023Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	69791000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax	-339000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	69452000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	114778000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax	-877000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	113901000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Term DebtSecuritiesAvailableForSaleTerm	P0Y2M26D
CY2023Q1	us-gaap	Litigation Reserve Current LitigationReserveCurrent	1400000	usd
CY2022Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	1400000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1203000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3967000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1628000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1172000	usd
CY2023Q1	sttk	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	10881000	usd
CY2022Q4	sttk	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	17795000	usd
CY2023Q1	sttk	License Agreement Royalty Payments Maximum LicenseAgreementRoyaltyPaymentsMaximum	20600000	usd
CY2023Q1	us-gaap	Payments For Royalties PaymentsForRoyalties	100000	usd
CY2023Q1	us-gaap	Accrued Royalties Current And Noncurrent AccruedRoyaltiesCurrentAndNoncurrent	0	usd
CY2022Q4	us-gaap	Litigation Settlement Amount Awarded To Other Party LitigationSettlementAmountAwardedToOtherParty	1400000	usd
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1683000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1513000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4209255	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.29
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y25D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1181087	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.57
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	717	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.95
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	128186	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	7.57
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5261439	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.25
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y25D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	5174691	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	7.27
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y18D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2122655	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	8.28
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y6M18D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.46
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.13
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	14100000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	100000	usd
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	100000	usd
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	200000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	200000	usd

Files In Submission

Name	View Source	Status
0001680367-23-000035-index-headers.html	Edgar Link	pending
0001680367-23-000035-index.html	Edgar Link	pending
0001680367-23-000035.txt	Edgar Link	pending
0001680367-23-000035-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
sttk-20230331.htm	Edgar Link	pending
sttk-20230331.xsd	Edgar Link	pending
sub-certxsection302xceoxq1.htm	Edgar Link	pending
sub-certxsection302xcfoxq1.htm	Edgar Link	pending
sub-certxsection906ofthesa.htm	Edgar Link	pending
sttk-20230331_def.xml	Edgar Link	unprocessable
sttk-20230331_cal.xml	Edgar Link	unprocessable
sttk-20230331_lab.xml	Edgar Link	unprocessable
sttk-20230331_pre.xml	Edgar Link	unprocessable
sttk-20230331_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$STTK
Shattuck Labs Inc Stock $sttk

2023 Q2 Form 10-Q Financial Statement

#000168036723000035 Filed on May 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$STTK Shattuck Labs Inc Stock $sttk

2023 Q2 Form 10-Q Financial Statement

#000168036723000035 Filed on May 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$STTK
Shattuck Labs Inc Stock $sttk